Shares of Quest PharmaTech Inc. (CVE:QPT – Get Free Report) traded down 14.3% during mid-day trading on Friday . The company traded as low as C$0.03 and last traded at C$0.03. 270,000 shares were traded during trading, an increase of 270% from the average session volume of 72,947 shares. The stock had previously closed at C$0.04.
Quest PharmaTech Stock Up 16.7%
The company has a market cap of C$5.92 million, a P/E ratio of -1.75 and a beta of 0.14. The stock’s 50-day moving average price is C$0.04 and its 200-day moving average price is C$0.03. The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Featured Articles
- Five stocks we like better than Quest PharmaTech
- How to Most Effectively Use the MarketBeat Earnings Screener
- Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making?
- 5 Top Rated Dividend Stocks to Consider
- Value Alert: 3 High-Yield Stocks Trading at 52-Week Lows
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
